Swiss Re Ltd / Key word: Research Update
Next wave of life expectancy gains is on the horizon, says Swiss Re report
22.05.2023 / 10:30 CET/CEST
Improvements in life expectancy. | May 22, 2023
In a research note published by Ivan Bokhmat, Barclays gives a Neutral rating to the stock. No major update to the target price set at CHF 96 compared to CHF 98. | May 22, 2023
Reinsurer Swiss Re
said on Monday it had decided to leave the Net-Zero
Insurance Alliance, without giving a reason for the decision.
It follows the exit of Munich Re at the end of
March, citing. | May 22, 2023
Analyst Hadley Cohen from Deutsche Bank research gives the stock a Neutral rating. The target price is being increased from CHF 85 to CHF 88. | May 9, 2023